Cyclophosphamide and Lupus Nephritis: When, How, For How Long?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Ever since the introduction of cyclophosphamide (CY), the management of lupus nephritis has dramatically changed, and its prognosis has greatly improved. Based on randomized controlled trials and long-term observational studies, pulse therapy with CY in combination with methyl-prednisolone (MP) is the “gold standard” of therapy for severe lupus. The realization of the significant gonadal toxicity intensified the efforts for the development of alternative immunosuppressive agents. In a large, randomized controlled trial, newer agents such as mycophenolate mofetil (MMF) have demonstrated comparable efficacy and less toxicity for moderately severe disease. To date, combinations of monthly pulses of CY with MP remain the gold standard for the induction of remission in severe lupus. For maintenance, less toxic agents such as azathioprine or MMF are equally effective and are routinely used in the current therapy of lupus.
- Cyclophosphamide and Lupus Nephritis: When, How, For How Long?
Clinical Reviews in Allergy & Immunology
Volume 40, Issue 3 , pp 181-191
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Induction therapy
- Maintenance therapy
- Lupus nephritis
- Randomized controlled trials
- Industry Sectors
- Author Affiliations
- 1. Department of Rheumatology, Clinical Immunology, and Allergy, University of Crete Medical School, Voutes, P. O. Box 2209, Heraklion, Greece
- 2. Department of Internal Medicine, University of Crete School of Medicine, Voutes, P. O. Box 2209, Heraklion, Greece